<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-21188" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Eosinophilic Pneumonia</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Pahal</surname>
            <given-names>Parul</given-names>
          </name>
          <aff>ISMMS Mount Sinai Hospital, NYC, NY</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Penmetsa</surname>
            <given-names>Gopi K.</given-names>
          </name>
          <aff>University Of Utah hospital</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Modi</surname>
            <given-names>Pranav</given-names>
          </name>
          <aff>DY Patil Hospital, Navi Mumbai, India</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sharma</surname>
            <given-names>Sandeep</given-names>
          </name>
          <aff>Mery Fitzgerald Hospital</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Parul Pahal declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Gopi Penmetsa declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Pranav Modi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Sandeep Sharma declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>4</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-21188.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Eosinophilic pneumonia includes a group of disorders characterized by an accumulation of eosinophilic infiltrates in the pulmonary parenchyma with or without peripheral blood eosinophilia. These include a broad range of lung conditions that occur due to infectious or non-infectious causes. This activity describes the pathophysiology of eosinophilic pneumonia and highlights the role of the interprofessional team in its management.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Review the causes of eosinophilic pneumonia.</p></list-item><list-item><p>Describe the evaluation of a patient suspected of having eosinophilic pneumonia.</p></list-item><list-item><p>Summarize the treatment options for eosinophilic pneumonia.</p></list-item><list-item><p>Outline the importance of improving care coordination among interprofessional team members to improve outcomes for patients affected by eosinophilic pneumonia.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=21188&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=21188">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-21188.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Eosinophilic pneumonia represents a heterogeneous group of lung disorders characterized by the presence of peripheral blood eosinophilia (defined as an eosinophilic count&#x02009;&#x0003e;&#x02009;500&#x02009;&#x000d7;&#x02009;10 cells/L) with either increased eosinophils in BAL fluid or eosinophilic infiltration of lung parenchyma demonstrated on lung biopsy. Eosinophilic lung diseases are further classified into Primary or Secondary based on the absence or presence of underlying identifiable etiology.</p>
        <p>Eosinophilic pneumonia refers to a primary eosinophilic disorder, which is further classified into acute eosinophilic pneumonia and chronic eosinophilic pneumonia&#x000a0;<xref ref-type="bibr" rid="article-21188.r1">[1]</xref><xref ref-type="bibr" rid="article-21188.r2">[2]</xref>.</p>
        <p>Acute eosinophilic pneumonia presents&#x000a0;as an acute febrile illness characterized by the presence of diffuse pulmonary infiltrates on imaging and can cause acute respiratory failure.</p>
      </sec>
      <sec id="article-21188.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Abnormally increased eosinophils in lung parenchyma occurs&#x000a0;due to infectious and non-infectious causes.</p>
        <p>Non-infectious causes include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Idiopathic</p>
          </list-item>
          <list-item>
            <p>Drug (phenytoin, ampicillin, nitrofurantoin, ranitidine, acetaminophen, iodides)</p>
          </list-item>
          <list-item>
            <p>Toxin-induced&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Environmental triggers</p>
          </list-item>
          <list-item>
            <p>Malignancy</p>
          </list-item>
          <list-item>
            <p>Allergic bronchopulmonary aspergillosis</p>
          </list-item>
          <list-item>
            <p>Hypereosinophilic syndromes</p>
          </list-item>
          <list-item>
            <p>Churg-Strauss syndrome</p>
          </list-item>
          <list-item>
            <p>Smoking</p>
          </list-item>
        </list>
        <p>Infectious causes of pulmonary eosinophilia are almost always due to&#x000a0;parasitic infections. These include ascariasis, Strongyloides, hookworms, filarial nematodes, Paragonimus, and Toxocara.<xref ref-type="bibr" rid="article-21188.r3">[3]</xref><xref ref-type="bibr" rid="article-21188.r4">[4]</xref><xref ref-type="bibr" rid="article-21188.r5">[5]</xref></p>
        <p>Cases of acutely eosinophilic pneumonia are mostly idiopathic. Parasitic infections and drug/toxin can also present acutely.<xref ref-type="bibr" rid="article-21188.r6">[6]</xref><xref ref-type="bibr" rid="article-21188.r7">[7]</xref><xref ref-type="bibr" rid="article-21188.r8">[8]</xref></p>
      </sec>
      <sec id="article-21188.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Idiopathic acute eosinophilic&#x000a0;pneumonia can occur at any age but is more common in males of age 20-40 years. Associations for the condition also exist with chronic myelogenous leukemia (CML), HIV infection, and smoking.</p>
        <p>The most common cohort for chronic eosinophilic pneumonia is white women with a peak incidence between 30-40 years. Asthma is present in 50 percent of these patients.</p>
      </sec>
      <sec id="article-21188.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Eosinophils are granulocytic white blood cells (WBCs), which are primarily tissue-dwelling cells. The main functions of eosinophils include host defense, inflammation modulation, and tissue destruction. Eosinophils play an important role in killing parasites, tumor cells, and respiratory epithelial cells.</p>
        <p>The normal absolute eosinophil count in the peripheral blood is 0 to 500 cells/microL. Eosinophilia is predominantly due to polyclonal expansion (reactive expansion) as compared to hematopoietic&#x000a0;clonal stem cell expansion, which is rare. A count of over 1500 increases the risk of tissue damage. However, it can also occur at low eosinophil count. In eosinophilic&#x000a0;lung diseases, eosinophils commonly affect parenchyma&#x000a0;and airways.&#x000a0;Based on the increase in eosinophils, eosinophilia can be:</p>
        <list list-type="bullet">
          <list-item>
            <p>Mild eosinophilia &#x0003c;1500</p>
          </list-item>
          <list-item>
            <p>Moderate eosinophilia 1500-5000</p>
          </list-item>
          <list-item>
            <p>Severe eosinophilia &#x0003e;5000</p>
          </list-item>
        </list>
        <p>Eosinophilic pneumonia occurs secondary to lung tissue damage by the activated eosinophils. The substances and chemical mediators released by these activated macrophages damage the tissues and contribute to the disease pathology. These include: <xref ref-type="bibr" rid="article-21188.r9">[9]</xref><xref ref-type="bibr" rid="article-21188.r10">[10]</xref><xref ref-type="bibr" rid="article-21188.r11">[11]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Toxic granule product release - epithelial cells and nerve damage</p>
          </list-item>
          <list-item>
            <p>Leukotriene and platelet-activating factor production cause contraction of smooth muscles and inflammatory cells recruitment</p>
          </list-item>
          <list-item>
            <p>The release of cytokines - tissue damage and remodeling</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-21188.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>In acute eosinophilic pneumonia, there is a marked infiltration of eosinophils in the alveolar spaces, bronchial walls, and, to a lesser extent, in the interstitium. Acute and/or organizing diffuse alveolar damage is present. However, granulomas or hemorrhage are absent.</p>
        <p>In chronic eosinophilic pneumonia, leukocytic infiltrates in alveolar air spaces and interstitium. The infiltrates are predominantly eosinophilic with macrophages, lymphocytes, and occasional plasma cells.</p>
      </sec>
      <sec id="article-21188.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Common symptoms include a cough, fever, dyspnea, night sweats.</p>
        <p>Acute eosinophilic pneumonia follows a rapid course with symptoms developing within two weeks. Myalgias and pleuritic chest pain with dyspnea may also be present, which can progress to respiratory failure. These patients can present with apparent acute lung injury or acute respiratory distress syndrome (ARDS) without any antecedent illness. However, extrapulmonary failure and shock are absent, which differentiates it from ARDS. On auscultation, diffuse crackles are present.</p>
        <p>Chronic eosinophilic pneumonia follows a progressive course. The presentation is subacute with&#x000a0;symptoms present&#x000a0;for months before diagnosis. These patients present with moderate weight loss besides the common symptoms. Over time, dyspnea progresses and presents with wheezing, especially in those with adult-onset asthma.</p>
      </sec>
      <sec id="article-21188.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p><bold>Idiopathic Acute eosinophilic pneumonia-</bold> is usually a diagnosis&#x000a0;of exclusion.&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Eosinophilia on BAL (&#x0003e;25% eosinophils)</p>
          </list-item>
          <list-item>
            <p>Marked leukocytosis, but blood eosinophilia is initially not common</p>
          </list-item>
          <list-item>
            <p>Serum IgE may be moderately elevated</p>
          </list-item>
          <list-item>
            <p>Pulmonary function tests reveal restrictive ventilatory defect with reduced DLCO</p>
          </list-item>
          <list-item>
            <p>Nonspecific chest radiographs with subtle ground-glass opacities - bilateral diffuse mixed ground-glass opacities develop as the disease progresses</p>
          </list-item>
          <list-item>
            <p>Small to moderate bilateral pleural effusions are common</p>
          </list-item>
          <list-item>
            <p>CT scan confirms the diagnosis but usually not required</p>
          </list-item>
          <list-item>
            <p>Fluid analysis- High pH and marked eosinophilia</p>
          </list-item>
        </list>
        <p><bold>Chronic eosinophilic pneumonia&#x000a0;</bold>- the diagnosis is based&#x000a0;on clinical, radiographic, and BAL findings and on the inability to document pulmonary or systemic infection.</p>
        <list list-type="bullet">
          <list-item>
            <p>Marked eosinophilia on bronchoalveolar lavage, typically accounting for more than 40 percent of white blood cells</p>
          </list-item>
          <list-item>
            <p>Moderate leukocytosis with peripheral blood eosinophilia in most patients</p>
          </list-item>
          <list-item>
            <p>Serum IgE&#x000a0;levels elevation is a feature in half of the patients</p>
          </list-item>
          <list-item>
            <p>Moderate normocytic, normochromic anemia with thrombocytosis is present.</p>
          </list-item>
          <list-item>
            <p>ESR is typically elevated</p>
          </list-item>
          <list-item>
            <p>Pulmonary function tests depend on the severity of the disease; it may be restrictive, obstructive, or normal.</p>
          </list-item>
          <list-item>
            <p>Peripheral infiltrates on chest radiographs. Infiltrates are mostly bilateral, located&#x000a0;in mid and upper lung zones.<xref ref-type="bibr" rid="article-21188.r12">[12]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-21188.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Supportive care with supplemental oxygen and glucocorticoids are the initial management in acute cases. While waiting for the culture results, starting mechanical ventilation and empiric antibiotics are valid therapeutic measures.</p>
        <p>Systemic glucocorticoid therapy (intravenous or oral) is&#x000a0;recommended for all and started as soon as possible for rapid improvement within 12-48 hours. However, the dose depends on the severity. Without glucocorticoid therapy, there is a&#x000a0;risk of progressive respiratory failure in acute eosinophilic pneumonia patients. Once the respiratory failure resolves, oral prednisone continued for 2-4 weeks with a subsequent slow taper over the next few weeks.</p>
        <p>There is a dramatic response to corticosteroids with rapid resolution of symptoms within an hour and complete resolution of infiltrates within a month.</p>
        <p>For chronic eosinophilic pneumonia, prednisone (40-60 mg) until two weeks after the resolution of symptoms and x-ray abnormalities. Treatment is maintained for at least three months and optimally for 6 to 9 months. Some patients may require longer maintenance. Later, inhaled corticosteroids can be started allowing discontinuation of oral steroids.<xref ref-type="bibr" rid="article-21188.r12">[12]</xref><xref ref-type="bibr" rid="article-21188.r13">[13]</xref></p>
      </sec>
      <sec id="article-21188.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <list list-type="bullet">
          <list-item>
            <p>Asthma/allergy</p>
          </list-item>
          <list-item>
            <p>Broncho-centric granulomatosis</p>
          </list-item>
          <list-item>
            <p>Bronchiolitis obliterans organizing pneumonia</p>
          </list-item>
          <list-item>
            <p>Infections - fungal (Coccidioidal infection, Aspergillus, Pneumocystis jirovecii)</p>
          </list-item>
          <list-item>
            <p>Interstitial lung diseases</p>
          </list-item>
          <list-item>
            <p>Malignancy<xref ref-type="bibr" rid="article-21188.r13">[13]</xref><xref ref-type="bibr" rid="article-21188.r14">[14]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-21188.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Once the diagnosis of acute eosinophilic pneumonia is established, and corticosteroid treatment started, the prognosis is excellent with a dramatic response to therapy.</p>
        <p>Sometimes prolonged glucocorticoid therapy may be required&#x000a0;when there is a&#x000a0;risk of recurrence; the prognosis is generally&#x000a0;good for patients with chronic eosinophilic pneumonia.<xref ref-type="bibr" rid="article-21188.r15">[15]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-21188.s12" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Eosinophilic pneumonia affects the lung and is predominantly idiopathic. It requires interprofessional care and the involvement of more than one subspecialty. This patient-centered&#x000a0;approach involving a primary care provider with a team of other health professionals, including a pulmonologist, physiotherapists, respiratory therapists, nurses, pharmacists, and support groups working together for&#x000a0;the patient, plays a vital role in improving the quality of care in pneumonia patients. Critical care nurses monitor patients, administer treatment, and are crucial to team communication. Pharmacists counsel patients about the importance of compliance with glucocorticoids and educate them about the side effects. The timely diagnosis and treatment are crucial, especially in patients with an acute presentation, as left untreated, it can progress to respiratory failure. [Level 5]</p>
      </sec>
      <sec id="article-21188.s13">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=21188&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=21188">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/lung-disease-respiratory-health/eosinophilic-pneumonia/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=21188">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/21188/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=21188">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-21188.s14">
        <title>References</title>
        <ref id="article-21188.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Allen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wert</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Eosinophilic Pneumonias.</article-title>
            <source>J Allergy Clin Immunol Pract</source>
            <year>2018</year>
            <season>Sep-Oct</season>
            <volume>6</volume>
            <issue>5</issue>
            <fpage>1455</fpage>
            <page-range>1455-1461</page-range>
            <pub-id pub-id-type="pmid">29735405</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21188.r2">
          <label>2</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Salahuddin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Anjum</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Cherian</surname>
                <given-names>SV</given-names>
              </name>
            </person-group>
            <chapter-title>Pulmonary Eosinophilia</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>5</month>
            <day>22</day>
            <pub-id pub-id-type="pmid">29261977</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21188.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bartal</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Sagy</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Barski</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Drug-induced eosinophilic pneumonia: A review of 196 case reports.</article-title>
            <source>Medicine (Baltimore)</source>
            <year>2018</year>
            <month>Jan</month>
            <volume>97</volume>
            <issue>4</issue>
            <fpage>e9688</fpage>
            <pub-id pub-id-type="pmid">29369189</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21188.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Weissler</surname>
                <given-names>JC</given-names>
              </name>
            </person-group>
            <article-title>Eosinophilic Lung Disease.</article-title>
            <source>Am J Med Sci</source>
            <year>2017</year>
            <month>Oct</month>
            <volume>354</volume>
            <issue>4</issue>
            <fpage>339</fpage>
            <page-range>339-349</page-range>
            <pub-id pub-id-type="pmid">29078837</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21188.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Xiaohong</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Yiping</surname>
                <given-names>XU</given-names>
              </name>
              <name>
                <surname>Meiping</surname>
                <given-names>LU</given-names>
              </name>
            </person-group>
            <article-title>[Clinical characteristics and etiology of children with hypereosinophilia].</article-title>
            <source>Zhejiang Da Xue Xue Bao Yi Xue Ban</source>
            <year>2016</year>
            <month>May</month>
            <day>25</day>
            <volume>45</volume>
            <issue>3</issue>
            <fpage>292</fpage>
            <page-range>292-6</page-range>
            <pub-id pub-id-type="pmid">27651195</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21188.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Blavier</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Thimmesch</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lebrun</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Bodart</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>[Acute idiopathic eosinophilic pneumonia in a teenager].</article-title>
            <source>Rev Med Liege</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>73</volume>
            <issue>9</issue>
            <fpage>439</fpage>
            <page-range>439-441</page-range>
            <pub-id pub-id-type="pmid">30188028</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21188.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Higashi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Nakamura</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tsuji</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ogami</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Matsumoto</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kawago</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Tokui</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hayashi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sakamaki</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Yamamoto</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Daptomycin-induced Eosinophilic Pneumonia and a Review of the Published Literature.</article-title>
            <source>Intern Med</source>
            <year>2018</year>
            <month>Jan</month>
            <day>15</day>
            <volume>57</volume>
            <issue>2</issue>
            <fpage>253</fpage>
            <page-range>253-258</page-range>
            <pub-id pub-id-type="pmid">29093391</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21188.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fayyaz</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Acute eosinophilic pneumonia associated with smoking: a case report.</article-title>
            <source>J Community Hosp Intern Med Perspect</source>
            <year>2018</year>
            <volume>8</volume>
            <issue>3</issue>
            <fpage>119</fpage>
            <page-range>119-122</page-range>
            <pub-id pub-id-type="pmid">29915648</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21188.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bhatt</surname>
                <given-names>NY</given-names>
              </name>
              <name>
                <surname>Allen</surname>
                <given-names>JN</given-names>
              </name>
            </person-group>
            <article-title>Update on eosinophilic lung diseases.</article-title>
            <source>Semin Respir Crit Care Med</source>
            <year>2012</year>
            <month>Oct</month>
            <volume>33</volume>
            <issue>5</issue>
            <fpage>555</fpage>
            <page-range>555-71</page-range>
            <pub-id pub-id-type="pmid">23001808</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21188.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bjerrum</surname>
                <given-names>OW</given-names>
              </name>
              <name>
                <surname>Fassi</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Madsen</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Stentoft</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Vestergaard</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>R&#x000f8;nnov-Jessen</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Pedersen</surname>
                <given-names>PT</given-names>
              </name>
              <name>
                <surname>Pulczynski</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Overgaard</surname>
                <given-names>UM</given-names>
              </name>
              <name>
                <surname>Andersen</surname>
                <given-names>CL</given-names>
              </name>
            </person-group>
            <article-title>[Eosinophilia].</article-title>
            <source>Ugeskr Laeger</source>
            <year>2018</year>
            <month>Sep</month>
            <day>10</day>
            <volume>180</volume>
            <issue>37</issue>
            <pub-id pub-id-type="pmid">30259829</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21188.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Felton</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Lucas</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Rossi</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Dransfield</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Eosinophils in the lung - modulating apoptosis and efferocytosis in airway inflammation.</article-title>
            <source>Front Immunol</source>
            <year>2014</year>
            <volume>5</volume>
            <fpage>302</fpage>
            <pub-id pub-id-type="pmid">25071763</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21188.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>De Giacomi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Vassallo</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Yi</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Ryu</surname>
                <given-names>JH</given-names>
              </name>
            </person-group>
            <article-title>Acute Eosinophilic Pneumonia. Causes, Diagnosis, and Management.</article-title>
            <source>Am J Respir Crit Care Med</source>
            <year>2018</year>
            <month>Mar</month>
            <day>15</day>
            <volume>197</volume>
            <issue>6</issue>
            <fpage>728</fpage>
            <page-range>728-736</page-range>
            <pub-id pub-id-type="pmid">29206477</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21188.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Seifert</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gerth</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gajda</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pester</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Pfeifer</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Wolf</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>[Eosinophilia--a challenging differential diagnosis].</article-title>
            <source>Med Klin (Munich)</source>
            <year>2008</year>
            <month>Aug</month>
            <day>15</day>
            <volume>103</volume>
            <issue>8</issue>
            <fpage>591</fpage>
            <page-range>591-7</page-range>
            <pub-id pub-id-type="pmid">18807233</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21188.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Curtis</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ogbogu</surname>
                <given-names>PU</given-names>
              </name>
            </person-group>
            <article-title>Evaluation and Differential Diagnosis of Persistent Marked Eosinophilia.</article-title>
            <source>Immunol Allergy Clin North Am</source>
            <year>2015</year>
            <month>Aug</month>
            <volume>35</volume>
            <issue>3</issue>
            <fpage>387</fpage>
            <page-range>387-402</page-range>
            <pub-id pub-id-type="pmid">26209891</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21188.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Martin</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Brightling</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Pavord</surname>
                <given-names>ID</given-names>
              </name>
            </person-group>
            <article-title>Eosinophils best marker of steroid response.</article-title>
            <source>Thorax</source>
            <year>2011</year>
            <month>Aug</month>
            <volume>66</volume>
            <issue>8</issue>
            <fpage>730; author reply 730</fpage>
            <page-range>730; author reply 730-1</page-range>
            <pub-id pub-id-type="pmid">20864573</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
